

BREAST CANCER IN ELDERLY PATIENTS

Breast cancer in the elderly: reducing the losses.

Markopoulos C, van de Water W, van de Velde CJ.

Future Oncol. 2013 Sep;9(9):1253-6.

Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

van de Water W, **Markopoulos C**, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, *et al.*

JAMA. 2012 Feb 8;307(6):590-7.

Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.

van de Water W, Seynaeve C, Bastiaannet E, **Markopoulos C**, Jones SE, Rea D, *et al.*

Oncologist. 2013;18(1):8-13.

Older patients with breast cancer: is there bias in the treatment they receive?

Markopoulos C, van de Water W.

Ther Adv Med Oncol. 2012 Nov;4(6):321-7.

Are we treating the elderly with breast cancer to the same standard as younger patients?

Markopoulos C, van de Water W.

Aging Health (2012) 8(1), 1–3.

OncotypeDX

Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.

Markopoulos C.

Expert Rev Anticancer Ther. 2013 Feb;13(2):179-94.

Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.

Markopoulos C, Xepapadakis G, Venizelos V, Tsiftoglou A, Misitzis J, Panoussis D, Antonopoulou Z, Stathouloupoulou M, Zobolas V, Gogas H.

Eur J Surg Oncol. 2012 May;38(5):413-9.

AROMATASE INHIBITORS

Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?

Aapro M, van de Velde CJ, **Markopoulos C**, Bartlett JM, Putter H, Coleman RE.

Breast. 2013 Feb 27.

Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis.

Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenburg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, **Markopoulos C**, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ.

J Clin Oncol. 2013 Apr 22.

Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.

Markopoulos C, Tzoracoleftherakis E, Koukouras D, Venizelos B, Zobolas V, Mitsizis J, Xepapadakis G, Gogas H.

J Cancer Res Clin Oncol. 2012 Sep;138(9):1569-77.

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, **Markopoulos C**, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE.

Lancet. 2011 Jan 22;377(9762):321-31.

Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.

Markopoulos CJ.

Cancer Metastasis Rev. 2010 Dec;29(4):581-94.

Management of anastrozole-induced bone loss in breast cancer patients

with oral risedronate: results from the ARBI prospective clinical trial.

Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H.

Breast Cancer Res. 2010;12(2):R24.

Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.

Markopoulos C, Dafni U, Misitzis J, Zobolas V, Tzoracoleftherakis E, Koukouras D, Xepapadakis G, Papadiamantis J, Venizelos B, Antonopoulou Z, Gogas H.

Breast Cancer Res. 2009;11(3):R35.

Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.

Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G, Gogas H.

Ann Oncol. 2009 Jan;20(1):49-55.

Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.

Markopoulos C.

Surg Oncol. 2008 Aug;17(2):113-28.

PSYCHOLOGICAL IMPLICATIONS

Impact of breast cancer surgery on the self-esteem and sexual life of female patients.

Markopoulos C, Tsaroucha AK, Kouskos E, Mantas D, Antonopoulou Z, Karvelis S.
J Int Med Res. 2009 Jan-Feb;37(1):182-8.

Depressive symptomatology correlates with phantom breast syndrome in mastectomized women.

Spyropoulou AC, Papageorgiou C, **Markopoulos C**, Christodoulou GN, Soldatos KR.
Eur Arch Psychiatry Clin Neurosci. 2008 Apr;258(3):165-70.

Development of early malignant bilateral breast disease in relation to antidepressant treatment.

Markopoulos C, Kouskos E, Phillipidis T.
Acta Chir Belg. 2005 Nov-Dec;105(6):660-1

Phantom breast syndrome: The effect of in situ breast carcinoma.

Markopoulos CJ, Spyropoulou AC, Zervas IM, Christodoulou GN, Papageorgiou C.
Psychiatry Res. 2010 Oct 30;179(3):333-7.